Few subjects in internal medicine generate as much confusion as hormone therapy. The information available to patients swings between two poles: it is dangerous and should be avoided, or it is the answer to nearly everything. Neither position survives contact with the evidence.
How we got here
Much of the current confusion traces back to the early reporting of the Women’s Health Initiative in 2002. The headlines were alarming, the nuance was lost, and prescribing collapsed almost overnight. Subsequent analysis has been considerably more measured, particularly regarding the age at which therapy begins and the formulation used. Many women who could have benefited were discouraged for two decades on the strength of a summary rather than the study.
The pendulum has since swung the other way. Hormone therapy is now marketed aggressively, frequently by clinics with little interest in whether a given patient is a reasonable candidate.
What the evidence supports
For women, hormone therapy remains the most effective treatment available for moderate to severe vasomotor symptoms, and it has an established role in preserving bone density. Timing matters a great deal. Risk and benefit look quite different for a woman beginning therapy near the onset of menopause than for one beginning many years later.
For men, testosterone therapy has a legitimate role in genuine, biochemically confirmed hypogonadism, diagnosed on the basis of symptoms together with repeated morning laboratory testing. It is not a treatment for ordinary fatigue, and it is not a performance enhancer. It carries real considerations around fertility, red blood cell counts, and prostate monitoring that require ongoing oversight.
Where marketing outruns the science
Compounded pellet therapy is heavily promoted and, once implanted, cannot be adjusted or removed if levels overshoot. Claims that compounded hormones are inherently safer than regulated preparations are not supported. Testing saliva rather than blood is not a validated approach. And treating a laboratory value in a patient with no symptoms is rarely good medicine.
How the decision should be made
Hormone therapy is a genuine clinical decision, not a product. It requires an accurate diagnosis, an honest discussion of what is known and what is uncertain, attention to your personal and family history, and monitoring over time with a willingness to stop if the balance changes.
Done carefully, it can meaningfully improve quality of life. Done casually, it is a risk taken for no clear reason. The difference is the physician relationship behind it.